[1] 龙琴, 白浪, 杜凌遥,等. 慢性乙型肝炎肝硬化患者使用核苷(酸)类似物抗病毒抗纤维化的临床疗效. 肝脏, 2016, 21:279-282.
[2] Lok ASF , Mcmahon BJ , Brown JRS , et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology, 2016, 63:284-306.
[3] 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2010年版). 肝脏, 2011, 3:66-82.
[4] Wang PC, Wei TY, Tseng TC , et al. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. Eur J Gastroenterol Hepatol, 2017, 29:946-950.
[5] Shim JJ, Oh CH, Kim JW , et al. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scand J Gastroenterol, 2017, 52:1029-1036.
[6] Chon YE, Park JY, Myoung SM, et al. Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis. Am J Gastroenterol, 2017, 112:882-891.
[7] Jonas MM, Lok AS, Mcmahon BJ , et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis. Hepatology, 2016, 63:307-318.
[8] Vourli G, Papatheodoridis G, Raptopoulou M, et al. Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study. Hippokratia, 2016, 20:214-221.
[9] 邓林, 张凡, 钱晨雨. HBV感染者肝纤维化四项指标检测值与Fibroscan检测值的相关性分析. 中国微生态学杂志, 2017, 29:1309-1311. |
